Information Provided By: 
Fly News Breaks for May 20, 2019
SNY, NVS, REGN
May 20, 2019 | 16:31 EDT
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.
News For REGN;NVS;SNY From the Last 2 Days
NVS
Apr 24, 2024 | 07:26 EDT
TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.
REGN
Apr 24, 2024 | 07:20 EDT
NVS
Apr 24, 2024 | 06:24 EDT
NVS
Apr 23, 2024 | 13:58 EDT
NVS
Apr 23, 2024 | 06:36 EDT
NVS
Apr 23, 2024 | 06:35 EDT
SNY
Apr 22, 2024 | 12:15 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
SNY
Apr 22, 2024 | 11:36 EDT
